-
Akeso, Inc. Has Made Positive Progress on Bispecific Antibody with Pipelines Enriched
PharmaSources/Chuxin
September 09, 2021
On August 24, Akeso, Inc. announced that the registered Phase II clinical research of its independently-developed global first new tumor immunotherapy drug...
-
Application Status and Market Prospect of Oral Membrane
PharmaSources/Shaluo
September 09, 2021
With the development and successful listing of several new oral membranes, this product has attracted wide attention at home and abroad since 2000.
-
A Brief Discussion on Roxadustat in the Midst of the Controversy
PharmaSources/zhulikou431
August 31, 2021
Recently, there is a good news for roxadustat, which is in the midst of the controversy. On August 19, 2021 local time, Astellas Pharma Inc. and FibroGen jointly announced that roxadustat was approved by the European Commission (EC) for adult patients.
-
Will EXO-CD24, the New Drug from Israeli, Bring COVID-19 to an End?
PharmaSources/Big Cat in the Pharma Industry
August 25, 2021
Recently, the issue that Israeli medical staff obtained a new drug named EXO-CD24 with remarkable curative effect on COVID-19 infection are making a lot of headlines on domestic media.
-
The Pharmaceutical Company Licenses in Two New Drugs for Dry Eye Disease with over 200 Million US Dollars
PharmaSources/Yefenghong
August 25, 2021
On August 5, Oyster Point Pharma, Inc. revealed on its official website that it has reached a cooperation agreement with Ji Xing Pharmaceuticals, which will develop and commercialize OC-01 (varenicline) and OC-02 (simpinicline) nasal sprays for patients.
-
Penpulimab, the Fifth Chinese PD-1 Monoclonal Antibody, was approved for Marketing
PharmaSources/Yefenghong
August 25, 2021
On August 5, penpulimab (AK105) developed by Akeso, Inc. was approved for marketing, which is used to treat patients with relapsed or refractory classic Hodgkin's lymphoma (r/r cHL) after second-line systemic chemotherapy.
-
A Review of the Three Chinese Patent Medicines Traditional Chinese Medicine to Treat COVID-19
PharmaSources/Miling
January 31, 2021
The Joint Prevention and Control Mechanism of the State Council of China has recently held a special press conference on the research progress of COVID-19 drug R&D and vaccine development, etc. According to the principal of the National Administration of
-
New Breakthrough in the Therapy of Hemophilia: Chinese Recombinant Coagulation Factor VIII has been Approved for Marketing
PharmaSources/Yefenghong
August 11, 2021
On July 23, according to latest announcement in the official website of the National Medical Products Administration (NMPA), the recombinant coagulation factor VIII (SCT800) for injection developed by Shenzhou Cell Biotechnology.
-
How Much Do You Know About Fighting AIDS - An Overview of AIDS Cocktail Therapy
PharmaSources/Xiaoyaowan
August 11, 2021
According to the data, the number of people infected with AIDS in the world reached 38 million in 2019, an increase of 1.88% year-on-year, including 1.7 million new cases.
-
Drug Research and Development of Targeting STAT3: Next Outlet for Antitumor Drugs
PharmaSources/Yuntian
August 11, 2021
STAT3 is a major member of signal transduction and activating transcription factor (STAT). According to some studies, it is verified that STAT3 can regulate the growth cycle and immune response of cells.